Department of Biology, Faculty of Life Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Department of Medical Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
Anticancer Agents Med Chem. 2019;19(13):1609-1617. doi: 10.2174/1871520619666190416114145.
Based on recent studies, new therapeutic strategies have been developed for cancer treatment using microRNAs (miRNAs). With this view, miRNAs manipulating techniques can be considered as novel therapeutic prospects for cancer treatment. In this study, we evaluated the expression of miR-4301 in human lung cancer cell lines and investigated its potential role in cell proliferation and tumor suppression on Non-Small Cell Lung Cancer (NSCLC) cells.
We used quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) to examine the level of miR- 4301 expression in human lung cancer cell lines (A549, QU-DB) and non-malignant lung epithelial cells (HFLF-PI5). Then, we investigated the effect of miR-4301 by transfecting it into these cell lines and probing for cancer cell viability and apoptosis using the MTT assay, flow cytometry and immunofluorescence staining.
Our results showed that the expression level of miR-4301 was significantly reduced in human lung cancer cell lines (P<0.001). When miR-4301 was transfected in lung cancer cells, their cell proliferation was suppressed and apoptosis induced. This decline in cell survival was confirmed by the MTT assay. Transfection of miR-4301 caused an increase in early and late apoptotic cells in all lung cancer cell lines tested.
Our findings show that miR-4301 may act as a lung cancer suppressor through targeting of proteins involved in cell proliferation and survival. For this reason, targeting miR-4301 may provide a new strategy for the diagnosis and treatment of patients with this deadly disease. This article is protected by copyright. All rights reserved.
基于最近的研究，已经开发出了使用 microRNAs（miRNAs）的癌症治疗新的治疗策略。有鉴于此，miRNAs 操作技术可以被视为癌症治疗的新的治疗前景。在这项研究中，我们评估了 miR-4301 在人肺癌细胞系中的表达，并研究了其在非小细胞肺癌（NSCLC）细胞中对细胞增殖和肿瘤抑制的潜在作用。
我们使用定量实时聚合酶链反应（qRT-PCR）来检查 miR-4301 在人肺癌细胞系（A549、QU-DB）和非恶性肺上皮细胞（HFLF-PI5）中的表达水平。然后，我们通过转染这些细胞系并使用 MTT 测定、流式细胞术和免疫荧光染色来探测癌症细胞活力和细胞凋亡来研究 miR-4301 的作用。
我们的结果表明，miR-4301 的表达水平在人肺癌细胞系中显著降低（P<0.001）。当 miR-4301 转染到肺癌细胞中时，它们的细胞增殖受到抑制，细胞凋亡被诱导。MTT 测定证实了这种细胞存活的下降。miR-4301 的转染导致所有测试的肺癌细胞系中的早期和晚期凋亡细胞增加。
我们的研究结果表明，miR-4301 可能通过靶向参与细胞增殖和存活的蛋白质作为肺癌抑制物发挥作用。因此，针对 miR-4301 可能为这种致命疾病的诊断和治疗提供新的策略。本文受版权保护。版权所有。
